111 related articles for article (PubMed ID: 30070937)
21. METTL3 restrains papillary thyroid cancer progression via m
He J; Zhou M; Yin J; Wan J; Chu J; Jia J; Sheng J; Wang C; Yin H; He F
Mol Ther; 2021 May; 29(5):1821-1837. PubMed ID: 33484966
[TBL] [Abstract][Full Text] [Related]
22. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
[TBL] [Abstract][Full Text] [Related]
24. A nomogram based on clinicopathological and ultrasound characteristics to predict central neck lymph node metastases in papillary thyroid cancer.
Chen F; Jiang S; Yao F; Huang Y; Cai J; Wei J; Li C; Wu Y; Yi X; Zhang Z
Front Endocrinol (Lausanne); 2023; 14():1267494. PubMed ID: 38410376
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel genomic variance of BRAF1 in papillary thyroid carcinoma: A case report.
Wang Y; Zhao J; Tan Z; Du J; Zhang L; Xu Y; Li X; Cai Y; Wang H; Jiang J
Medicine (Baltimore); 2024 Jan; 103(3):e36978. PubMed ID: 38241570
[TBL] [Abstract][Full Text] [Related]
26. Age and
Huang G; Liu W; Han L; Zhang Y; Liu S; Zhang J; Niu B
Int J Gen Med; 2023; 16():6025-6039. PubMed ID: 38148884
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a dynamic nomogram based on conventional ultrasound and contrast-enhanced ultrasound for stratifying the risk of central lymph node metastasis in papillary thyroid carcinoma preoperatively.
Chen Q; Liu Y; Liu J; Su Y; Qian L; Hu X
Front Endocrinol (Lausanne); 2023; 14():1186381. PubMed ID: 37409231
[TBL] [Abstract][Full Text] [Related]
28. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer.
Ye G; Zhang X; Li M; Lin Z; Xu Y; Dong H; Zhou J; Zhang J; Wang S; Zhu Y; Yu X; Qian X
BMC Cancer; 2023 May; 23(1):412. PubMed ID: 37158852
[TBL] [Abstract][Full Text] [Related]
29. Identification of KIT and BRAF mutations in thyroid tissue using next-generation sequencing in an Ecuadorian patient: A case report.
Cadena-Ullauri S; Paz-Cruz E; Tamayo-Trujillo R; Guevara-Ramírez P; Ruiz-Pozo V; Solis-Pazmino P; Garcia C; Godoy R; Lincango-Naranjo E; Zambrano AK
Front Oncol; 2022; 12():1101530. PubMed ID: 36733350
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and meta-analysis comparing tumor progression and complications between radiofrequency ablation and thyroidectomy for papillary thyroid carcinoma.
Sun YD; Zhang H; Zhu HT; Wu CX; Chen ML; Han JJ
Front Oncol; 2022; 12():994728. PubMed ID: 36530996
[TBL] [Abstract][Full Text] [Related]
31. A Potential Four-Gene Signature and Nomogram for Predicting the Overall Survival of Papillary Thyroid Cancer.
Ding Y; Li P; Wang W; Liu F
Dis Markers; 2022; 2022():8735551. PubMed ID: 36193505
[TBL] [Abstract][Full Text] [Related]
32. Concepts of Pathological Staging and Prognosis in Papillary Thyroid Carcinoma.
Lam AK
Methods Mol Biol; 2022; 2534():109-119. PubMed ID: 35670971
[TBL] [Abstract][Full Text] [Related]
33. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Recurrence in Patients with Papillary Thyroid Carcinoma: Does Male Sex Matter?
Kim H; Kwon H; Moon BI
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454803
[TBL] [Abstract][Full Text] [Related]
35. Male patients with papillary thyroid cancer have a higher risk of extranodal extension.
Hei H; Zhou B; Gong W; Zheng C; Qin J
Int J Clin Oncol; 2022 Apr; 27(4):648-654. PubMed ID: 35000041
[TBL] [Abstract][Full Text] [Related]
36. Sex Bias in Differentiated Thyroid Cancer.
Suteau V; Munier M; Briet C; Rodien P
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884794
[TBL] [Abstract][Full Text] [Related]
37. A two-microRNA signature predicts the progression of male thyroid cancer.
Liu B; Shi H; Qiu W; Wu X; Li L; Wu W
Open Life Sci; 2021; 16(1):981-991. PubMed ID: 34595349
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
Front Endocrinol (Lausanne); 2021; 12():646793. PubMed ID: 34122331
[TBL] [Abstract][Full Text] [Related]
39. Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma.
Póvoa AA; Teixeira E; Bella-Cueto MR; Batista R; Pestana A; Melo M; Alves T; Pinto M; Sobrinho-Simões M; Maciel J; Soares P
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922635
[TBL] [Abstract][Full Text] [Related]
40. Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.
Hu J; Yuan IJ; Mirshahidi S; Simental A; Lee SC; Yuan X
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
